Indian Journal of Pharmaceutical Sciences
Users online: 134
Scientific Publication of the Indian Pharmaceutical Association
Home Email this page Print this page Bookmark this page Decrease font size Default font size Increase font size
The Journal Search Current Issue Archives Instructions Online submission Login  


 
SHORT COMMUNICATION
Year : 2008  |  Volume : 70  |  Issue : 1  |  Page : 91-94
In vitro antiviral activity of some novel isatin derivatives against HCV and SARS-CoV viruses


1 Arulmigu Kalasalingam College of Pharmacy, Krishnankoil - 626 190, India
2 Institute of Pharmacology, Madurai Medical College, Madurai - 625 020, India
3 Bharat Ratna Kamarajar Liver Hospital and Research Center, Madurai - 625 001, India
4 Raga Institute for Medical Research, Katholieke Universiteit-Leuven, Minder broederstraat 10, LeuvenB-3000, Belgium

Date of Submission06-Jul-2006
Date of Decision23-Jul-2007
Date of Acceptance29-Jan-2008

Correspondence Address:
P Selvam
Arulmigu Kalasalingam College of Pharmacy, Krishnankoil - 626 190
India
Login to access the Email id


DOI: 10.4103/0250-474X.40339

PMID: 20390088

Get Permissions

   Abstract 

4-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)amino]-N(4,6-dimethyl-2-pyrimidiny)benzene sulphonamide and its derivatives were evaluated for antiviral activity against Pathogenic viruses such as Hepatitis C Virus and SARS-CoV in Vero and Huh 5-2 cells, respectively. The 5-fluoro derivative inhibited the HCV RNA synthesis at 6 g/ml, without toxicity at a concentration up to 42 g/ml in Huh 5-2 cells. Among the compounds tested SPIII-5F exhibits the 45% maximum protection against replication of SARS-CoV in Vero cells.


Keywords: Isatin, HCV, SARS-CoV, vero cells, huh 5-2 cells


How to cite this article:
Selvam P, Murgesh N, Chandramohan M, De Clercq E, Keyaerts E, Vijgen L, Maes P, Neyts J, Ranst M V. In vitro antiviral activity of some novel isatin derivatives against HCV and SARS-CoV viruses. Indian J Pharm Sci 2008;70:91-4

How to cite this URL:
Selvam P, Murgesh N, Chandramohan M, De Clercq E, Keyaerts E, Vijgen L, Maes P, Neyts J, Ranst M V. In vitro antiviral activity of some novel isatin derivatives against HCV and SARS-CoV viruses. Indian J Pharm Sci [serial online] 2008 [cited 2014 Apr 25];70:91-4. Available from: http://www.ijpsonline.com/text.asp?2008/70/1/91/40339


Isatin (2,3-dioxoindole), a versatile lead molecule for potential bioactive agents, and its derivatives were reported to posses anticancer [1] , antibacterial activities [2],[3],[4] . Methisazone (N-methylisatin-β -thiosemicarbazone) was one of the first clinically used synthetic antiviral agent [5] . Isatin derivative were reported for antiviral activity against a verity of pathogens viruses [6] and N,N-disubstitutedthiosemicarbazone derivative of isatin were tested for inhibition of HIV-1 replication [7] . Previously we reported synthesis of novel isatin derivatives and evaluated antiviral activity against HIV-1 and HIV-2 in MT-4 cells [8] . Significant antiviral activity was observed with these compounds against HIV-1 replication [9] .

In view of the broad spectrum activities of isatin derivatives, we aimed at evaluating the antiviral activity of some novel 4-1[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)amino]-N(4,6-dimethyl-2-pyrimidiny)-benzenesulphonamide and its derivatives [Figure - 1] against pathogenic viruses such as hepatitis C virus (HCV) in human hepatoblastoma cells (Huh 5-2 cells) and Severe Acute Respiratory Syndrome corona virus (SARS-CoV) in Vero cultures.

4-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)amino]-N(4,6-dimethyl-2-pyrimidiny)benzene sulphonamide and its derivatives [Figure - 1] were prepared by condensing the isatin and its derivatives (5-chloro, 5-bromo, 5-flouro, 5-methyl and N-acetyl) with sulphadimidine in the presence of glacial acetic acid [9] .

In the method adopted for antiviral activity against SARS-CoV in vero cells [10] . Vero E6 cells in 96-well tissue culture plates were used confluent. Culture medium was removed and 100 μL of minimum essential medium supplemented with 2% fetal bovine serum containing an appropriate concentration of antiviral compound was added. Inside a biosafety laboratory-3,25 μL of a SARS-CoV virus solution added. Five concentrations were tested for cytotoxicity of the antiviral compounds. After an incubation period of three days at 37 in 5% CO 2 , the inhibition of the cytopathic effect (CPE) by the compounds was measured in a spectrophotometer (at 492) by the reduction by cellular dehydrogenase of the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrzolium(MTS) dye (Cell titer 96 Aqueous One Solution kit, promega) (20 μL MTS for 3h at 37) in to a water soluble coloured formazan product. The antiviral activity and cytotoxcity of the test compounds are presented in [Table - 1].

Replication assay undertaken with Huh-5-2 cells [11],[12],[13] [a cell line with a persistent HCV replication 1389luc-ubi-neo/NS3-3/5.1; replication with firefly luciferase-lubquitin-neomycine phosphotransferase fusion protein EMCV-IRES drivan NS3-5B HCV polyprotein] was cultured in RPMI medium 2 mM glutamine, 1 non essential amino acid (Life Technologies, DC); 100 IU/ml penicillin and 100 μg/ml streptomycin and 250 μg/ml G418 (Geneticin, Life Technologies Washington DC). Cells were seeded at a density of 7000 cells per well in 96 well view plate TM (Packard, CA) in medium containing the same compounds as described above, except for G418. Cells were allowed to adhere and proliferate for 24 h. At that time, culture was removed and serial dilution of test compounds were added in culture medium lacking G418. Interferon alfa 2a (500 IU) was added as a positive control. Plates were further incubated at 37 and 5% CO 2 for 72 h replication of HCV replicon in Huh-5 cells results in luciferase activity in the cells. Luciferase activity was measured by adding 50 μl of 1 x Gloysis buffer (Promega) for 15 min of followed by adding 50 μl Steady-Glo Luciferase assay reagent (promega). Luciferase activity was measured with luminometer and signal in each individual well was expressed as a percentage of the untreated culture. Parallel culture of Huh 5-2 cells, seeded at a density of 7000 cells/well of classical 96-well cell culture plates (Becton-Dicknson) were treated in a similar fashion except that no Glo-lysis buffer or Stady-Glo Luciferase reagent was added. Instead the density of the cluture was measured by means of the MTS method (Promega). The antiviral activity and cytotoxicity of the test compounds are prepared in [Table - 2].

From the antiviral and cytotoxicity assay it was observed that the compounds 4-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)amino]-N(4,6-dimethyl-2-pyrimidiny)benzene sulphonamide (SPIII-5H) and bromo derivative (SPIII-Br) inhibits HCV RNA synthesis at the EC 50 of 17 and 19 μg/ml, respectively while its CC50 for cell growth was 42 μg/ml in Huh 5-2 cells. The isatin lead molecule 5Cl-IS-AC did not inhibit the HCV RNA synthesis (EC50 and CC 50 more than 50 μg/ml) and the replication of SARS-CoV (maximum protection 0%). SPIII derivative showed 2-45% maximum protection against the replication of SARS-CoV in Vero cells and compound SPIII 5F exhibited 45% maximum protection against the replication of acutely infected SARS-CoV in Vero cell.

The present study was aimed at investigating some novel isatin derivative for antiviral activities against HCV and SARS-CoV to identify potential bioactive agent in the series. From the results of biological activities it appeared that some of the derivatives showed antiviral activity against HCV virus in Huh 5-3 cells.SPIII-5H and bromo derivatives inhibited the synthesis of HCV RNA, but only at a relatively high concentration (17 and 19 μl/ml).

In the present study, the test compound SPIII-5F inhibited the HCV RNA synthesis in Huh 5-2 Cells (SI=7) and 45% maximum protection against the replication against the replication of acutely infected SARS-CoV in Vero cells [Table - 1],[Table - 2]. Isatin lead molecule (5CI-IS-AC) did not inhibit the HCV RNA synthesis and replication of SARS-CoV. Presence of sulphonamide side chain in the 3 rd position was essential for antiviral activity (SPIII-5H, 5Br and 5F). Further modification in the series may help in optimizing antiHCV activity.

 
   References Top

1.Popp FD. Synthesis of potential anti-neoplastic agents, XX: Compounds related to the 3-o-nitrophenylhydrazone of isatin. J Pharm Sci 1969;12:182-4.  Back to cited text no. 1    
2.Varma, RS, Nobles WL, Synthesis and Antiviral and Antibacterial Activity of Certain N-Dialkylaminomethylisatin β -Thiosemicarbazones. J Med Chem 1967;10:972-4.  Back to cited text no. 2    
3.Pandeya SN, Sriram D, De Clercq E, Pannecouque C, Witvrouw M. Anti-HIV activity of some Mannich bases of isatin derivatives. Indian J Pharm Sci 1998;60:207-12.  Back to cited text no. 3    
4.Pandeya SN, Sriram D, Nath G, De Clercq E. Synthesis, antibacterial, antifungal and anti-HIV activities of Norfloxacin Mannich bases. Eur J Med Chem 2000;35:249-55.  Back to cited text no. 4    
5.Bauer DJ, Sadler PW. The structure-activity relationships of the antiviral chemotherapeutic activity of isatin β-thiosemicarbazone. Br Pharm Chemother 1960;15:101-10.  Back to cited text no. 5    
6.Wolf ME, Antiviral agents: Burger Medicinal Chemistry, 4th ed., Part-II, New York: John Wiley and Sons; 1979. p. 553.  Back to cited text no. 6    
7.Teitz Y, Ronen D, Vansover A, Stematsky T, Rigg JL. Inhibition of human immunodeficiency virus by N-methylisatin-β -4':4' diethylthiosemicarbazone and N-allyl isatin-β -4':4' diallylthiosemicarbazone. Antiviral Res 1994;24:305-14.  Back to cited text no. 7    
8.Pauwels R, Balzarini J, Baba M, Snoeck R, Schols DJ, Herdewijin P, et al. Rapid and automated tetrazolium based colourimetric assay for the detection of anti-HIV compounds. J Virol Methods 1988;20:309-21.  Back to cited text no. 8    
9.Selvam P, Chandramohan M, De Clercq E, Pannecouque C, Witrouw M. Synthesis and anti-HIV activity of 4-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene) amino]-N (4, 6-dimethyl-2-pyrimidinyl)-benzenesulphonamide and its derivatives. Eur J Pharm. Sci 2001;14:313-6.  Back to cited text no. 9    
10.Keyaerts E, vijgen L, Maes P, Neyts J, Ranst MV. In vitro inhibition of SARS-CoV Virus by Chloroquine, Biochem Biophys Res Commun 2004;323:264-7.  Back to cited text no. 10    
11.Bartenschalager R. Hepatitis C virus replicons: Potential role for drug development. Nature Rev Drug Disc 2002;1:911-6.  Back to cited text no. 11    
12.Pietschman T, Lohmann V, Rutter G, Kurpanek K, Bartenschlager R. Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J Virol 2001;75:1252-64.  Back to cited text no. 12    
13.Lohmann V, Korner F, Koch J, Herian V, Theilmann L, Bartenschlager R, Replication of subgenomic hepatitis virus RNAs in a hepatoma cell line. Science 1999;285:110-3.  Back to cited text no. 13    


    Figures

  [Figure - 1]
 
 
    Tables

  [Table - 1], [Table - 2]

This article has been cited by
1 Microwave Mediated Organic Reaction: A Convenient Approach for Rapid and Efficient Synthesis of Biologically Active Substituted 1,3-Dihydro-2H-indol-2-one Derivatives
Jnyanaranjan Panda,Biswa Mohan Sahoo,Nikunja Kishor Mishra,Sai Krushna Padhi,Jitendriya Mishra
Journal of Nanomaterials. 2013; 2013: 1
[Pubmed]
2 Synthesis and antimicrobial potential of Mannich bases of 4-chloro-3-{4-(chlorobenzyloxy)-benzoylhydrazono}-indolin-2-ones
Rastogi, N., Harrison, D.A., Tripathi, D., Shukla, S.
Journal of the Indian Chemical Society. 2009; 86(9): 991-995
[Pubmed]



 

Top
Print this article  Email this article
 
  Search
   
   Next article
   Previous article 
   Table of Contents
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Article in PDF (221 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    Abstract
    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed3642    
    Printed149    
    Emailed0    
    PDF Downloaded352    
    Comments [Add]    
    Cited by others 2    

Recommend this journal